rituximab

Response to: ‘Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’’ by Tampe et al
Marcia A Friedman, Kevin L Winthrop

Annals of the Rheumatic Diseases Jun 2023, 82 (6) e133; DOI: 10.1136/annrheumdis-2021-220398
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
Victoria Furer, Tali Eviatar, Devy Zisman, Hagit Peleg, Daphna Paran, David Levartovsky, Michael Zisapel, Ofir Elalouf, Ilana Kaufman, Roni Meidan, Adi Broyde, Ari Polachek, Jonathan Wollman, Ira Litinsky, Katya Meridor, Hila Nochomovitz, Adi Silberman, Dana Rosenberg, Joy Feld, Amir Haddad, Tal Gazzit, Muna Elias, Nizar Higazi, Fadi Kharouf, Gabi Shefer, Orly Sharon, Sara Pel, Sharon Nevo, Ori Elkayam

Annals of the Rheumatic Diseases Oct 2021, 80 (10) 1330-1338; DOI: 10.1136/annrheumdis-2021-220647
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial
Michael Bonelli, Daniel Mrak, Selma Tobudic, Daniela Sieghart, Maximilian Koblischke, Peter Mandl, Barbara Kornek, Elisabeth Simader, Helga Radner, Thomas Perkmann, Helmuth Haslacher, Margareta Mayer, Philipp Hofer, Kurt Redlich, Emma Husar-Memmer, Ruth Fritsch-Stork, Renate Thalhammer, Karin Stiasny, Stefan Winkler, Josef S Smolen, Judith H Aberle, Markus Zeitlinger, Leonhard X Heinz, Daniel Aletaha

Annals of the Rheumatic Diseases May 2022, 81 (5) 687-694; DOI: 10.1136/annrheumdis-2021-221558
Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases
Jerome Hadjadj, Delphine Planas, Amani Ouedrani, Solene Buffier, Laure Delage, Yann Nguyen, Timothée Bruel, Marie-Claude Stolzenberg, Isabelle Staropoli, Natalia Ermak, Laure Macraigne, Caroline Morbieu, Soledad Henriquez, David Veyer, Hélène Péré, Marion Casadevall, Luc Mouthon, Frederic Rieux-Laucat, Lucienne Chatenoud, Olivier Schwartz, Benjamin Terrier

Annals of the Rheumatic Diseases May 2022, 81 (5) 720-728; DOI: 10.1136/annrheumdis-2021-221508
Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis
Claudius Speer, Maximilian Töllner, Louise Benning, Katrin Klein, Marie Bartenschlager, Christian Nusshag, Florian Kälble, Paula Reichel, Paul Schnitzler, Martin Zeier, Christian Morath, Wilhelm H Schmitt, Raoul Bergner, Ralf Bartenschlager, Matthias Schaier

Annals of the Rheumatic Diseases Apr 2022, 81 (4) 593-595; DOI: 10.1136/annrheumdis-2021-221747
Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study
Alessandra Bettiol, Maria Letizia Urban, Federica Bello, Davide Fiori, Irene Mattioli, Giuseppe Lopalco, Florenzo Iannone, Allyson Egan, Lorenzo Dagna, Marco Caminati, Simone Negrini, Elena Bargagli, Marco Folci, Franco Franceschini, Roberto Padoan, Oliver Flossmann, Roser Solans, Jan Schroeder, Marc André, Laura Moi, Paola Parronchi, Dario Roccatello, Savino Sciascia, David Jayne, Domenico Prisco, Augusto Vaglio, Giacomo Emmi

Annals of the Rheumatic Diseases Dec 2022, 81 (12) 1769-1772; DOI: 10.1136/ard-2022-222776
Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series
Peter Kvacskay, Wolfgang Merkt, Janine Günther, Norbert Blank, Hanns-Martin Lorenz

Annals of the Rheumatic Diseases May 2022, 81 (5) 744-746; DOI: 10.1136/annrheumdis-2021-221756
Approach to vaccination in systemic lupus erythematosus on biological treatment
Reşit Yıldırım, Tatiana Oliveira, David Alan Isenberg

Annals of the Rheumatic Diseases Sep 2023, 82 (9) 1123-1129; DOI: 10.1136/ard-2023-224071
Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Mathian et al
Quirin Notz, Patrick Meybohm, Peter Kranke, Dirk Weismann, Christopher Lotz, Marc Schmalzing

Annals of the Rheumatic Diseases Nov 2022, 81 (11) e216; DOI: 10.1136/annrheumdis-2020-218778
Response to: ‘Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian et al’ by Notz et al
Alexis Mathian, Zahir Amoura

Annals of the Rheumatic Diseases Nov 2022, 81 (11) e217; DOI: 10.1136/annrheumdis-2020-218795

Main menu

rituximab

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

rituximab

Pages